NHWA Pharma Gains China Fast-Track for Epilepsy Drug

Jiangsu NHWA Pharma announced that DP-VPA, its in-licensed epilepsy treatment, was granted Fast Track designation by the CFDA. DP-VPA combines a well-known generic drug for epilepsy, valproic acid (VPA), with a lipid coating to minimize side effects. In 2011, NHWA acquired exclusive China rights (including Hong Kong and Macau) to DP-VPA from D-Pharm, an Israeli biopharma. More details... Stock Symbols: (SHE: 002262) (TASE:DPRM) Share this with colleagues: // //